Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.55 |
| ▸ | BDKRB1 | P46663 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 3/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717773 | 0.90 | BDKRB1 (0.56) | ACHEGSK3BBDKRB1F10 | |
| SCHEMBL4761371 | 0.88 | BDKRB1 (0.68) | ACHEGSK3BBDKRB1F10 | |
| SCHEMBL4711922 | 0.88 | BDKRB1 (0.60) | ACHEGSK3BBDKRB1NPC1RAB9A | |
| SCHEMBL5631292 | 0.86 | CXCR3 (0.55) | ACHEGSK3BCXCR3BDKRB1F10 | |
| SCHEMBL6045875 | 0.85 | BDKRB1 (0.55) | ACHEGSK3BCXCR3BDKRB1NPC1 | |
| SCHEMBL4713232 | 0.83 | BDKRB1 (0.53) | BDKRB1 | |
| SCHEMBL4712113 | 0.81 | BDKRB1 (0.59) | ACHEGSK3BCXCR3BDKRB1F10 | |
| SCHEMBL4716382 | 0.79 | BDKRB1 (0.67) | ACHEGSK3BBDKRB1RAB9ASMN1; SMN2 | |
| SCHEMBL6066754 | 0.78 | F10 (0.62) | F10 | |
| SCHEMBL4716746 | 0.78 | F10 (0.56) | BDKRB1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | ACHE 2716/4885GSK3B 4572/4885CXCR3 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.